11th Annual BioBusiness Bio-partnering Conference

08:30 Networking and refreshments Networking and refreshments

09:00 Chairperson's welcoming remarks Simon Haworth, MD, Team Ventures Inc. No session description available. Simon Haworth MD, Team Ventures Inc. Simon’s first career was in real estate, second career in team building and third career in fundraising.Simon established the Market Research function for international property agent Savills plc, where he gained his first IPO experience. He moved on to Arthur Andersen to develop his corporate finance skills and by then had already esta [read more]

09:10 Leadership & CEO Panel: If I knew then what I know now - top down perspectives from key decision makers in biopharma Onno van de Stolpe, Chief Executive Officer, Galapagos Malcolm Weir, Chief Executive Officer, Heptares Therapeutics Philippe Van Holle, President EMEA, Celgene Simon Sturge, Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim Mike Ward, Editor, Scrip Intelligence Challenges faced in meeting organisational strategy The evolving role of the fully-integrated pharma company Overcoming entropy in the ideology of what the industry must do to drive innovation and patient value The challenge of funding and correlation with clinical failure Addressing mistakes of the past and the resulting paradigm shifts Moderator: Mike Ward Onno van de Stolpe Chief Executive Officer, Galapagos Onno van de Stolpe (CEO) founded Galapagos in 1999 and has grown the Company to its current level of about 800 employees. Galapagos is an integrated drug discovery company with a number of internal programs and two service divisions BioFocus and Argenta. For its internal programs, Galapagos has GSK, J&J, Roche and Servier as alliance partners. In these programs Gal [read more] Malcolm Weir Chief Executive Officer, Heptares Therapeutics Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to dr [read more] Philippe Van Holle President EMEA, Celgene Simon Sturge Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim Simon joined Boehringer Ingelheim GmbH as Corporate Senior Vice President Biopharmaceuticals on January 3rd, 2011. Having graduated with a Bachelor of Science from the University of Sussex in the UK, Simon entered industry almost 30 years ago in 1981. He initially joined Napp Laboratories, the UK subsidiary of a global U.S.-based pharmaceutical company and initi [read more] Mike Ward Editor, Scrip Intelligence Mike Ward is editor-in-chief at the Scrip Group focusing on the business challenges facing all stakeholders in the pharma, biotech and medtech industries. He has been covering the life sciences industry for more than 25 years. He has extensive experience in investment banking, consultancy as well as writing about the industry for other leading publications such [read more]

09:40 Powerpoint-free, off the record case study: The anatomy of a mega-merger – Analysing the Roche/Genentech fusion two years on James Sabry, Vice President, Genentech Partnering, Genentech Joseph McCracken, Global Head for Business Development & Licensing, Roche Back in March 2009, Roche announced a $46.8 billion deal to buy Genentech. But the path to a merged Roche and Genentech was far from smooth. Set to the background of an immense global recession and the challenge of preserving Genentech’s very different company culture – which in the course of its prior 19 year collaboration produced Roche’s best selling biologics – the deal presented many challenges along the way. This intimate panel will feature key executives behind the deal providing a behind the scenes 2 year appraisal of the historic deal, how they’ve managed to maintain a culture of innovation and what this means for future mergers, alliances and partnerships. Moderator: Simon Haworth James Sabry Vice President, Genentech Partnering, Genentech James Sabry is Vice President, Genentech Partnering, where he oversees both the gRED Business Development and Alliance Management groups. These groups have been considered to be some of the best in the industry at sourcing, negotiating, closing and managing business development relationships across discovery research, technology acquisition and clinical developm [read more] Joseph McCracken Global Head for Business Development & Licensing, Roche Joseph McCracken is currently the Global Head for Business Development & Licensing for Roche Pharma Partnering. In this role Dr. McCracken is responsible for Roche’s Pharma’s in-licensing and out-licensing activities, and he is currently based in Nutley, New Jersey. Prior to joining the Roche Pharma Partnering organization, Dr. McCracken held the [read more]

Morning refreshments and networkingSpeaker's Corner 10:30 Morning refreshments and networking Morning refreshments and networking Morning refreshments and networking 10:30 Speaker's Corner Speaker's Corner During the break, visit an area of the event dedicated to interaction with the previous session's speakers and panellists. This is your opportunity to network and speak openly about any questions not covered during their session.

Stream A: Payers Perspectives: A key part of the innovat...Stream B: Behind Closed Doors - Deal trends and case stu... 11:00 Payers Perspectives: Stream A: Payers Perspectives: A key part of the innovation process How the payers’ perspective has become a key part of the innovation process, how it impinges the final outcome and how it should be carefully integrated within the drug discovery and development process 11:00 Behind Closed Doors: Stream B: Behind Closed Doors - Deal trends and case studies Analysing the most interesting and innovative deals of 2011 and discovering the key drivers and outcomes behind them

Stream A: Payers Perspectives: A key part of the innovat...Stream B: Behind Closed Doors - Deal trends and case stu... 11:00 Keynote:Biotech needs a payer’s perspective – how knowing your value up front is key to future deal-making Stream A: Payers Perspectives: A key part of the innovation process Herve Lilliu, Vice President Global Health Outcomes, Market Access and Pricing, UCB In future, reimbursement at a meaningful level will require products that have significant differentiation as opposed to just the required regulatory package. Comparative Effectiveness Research demands best in class demonstration of brand value Differentiation from and direct comparison to standard of care is crucial Probability of Success focusing solely on Marketing Authorization is not enough for accurate NPV estimates Importance of bringing value to patients, payers and providers in the areas of unmet medical need Real life effectiveness, humanistic and economic components of brand value become as important as clinical endpoint Industry scorecard Big pharma – some embracing this better than others How pharma is adapting to address this changing landscape Interfacing with regulatory agencies and payers worldwide Biotech – still a long way to go Having a new mechanism of action isn’t enough to secure a pharma partner Developing a go-to-market strategy – what pharma will look at Herve Lilliu Vice President Global Health Outcomes, Market Access and Pricing, UCB Hervé is Vice President of Global Market Access and Pricing at Brussels based biopharmaceutical company UCB. He is responsible for strengthening and consolidating a cross functional team of health economics, patient-reported outcomes, epidemiology, market access and pricing professionals. His team is leading on the development and the implementation of market ac [read more] 11:00 Panel: Deconstructing deal trends – Where structures, up-fronts and pricing trends are going, and why there is so much disagreement between pharma and biotech on this Stream B: Behind Closed Doors - Deal trends and case studies Denise Goode, Executive Transaction Director, AstraZeneca Ian Nicholson, Chief Executive Officer, Chroma Therapeutics Ltd David Colpman, Senior Vice President, Business Development, Shire Pharmaceuticals There exists a sharp disparity between biotech and pharma views on pricing and upfront trends, with the majority of pharma believing there to be an upward trend and the reverse being true for biotech opinions – both sides seeing the trend going against their interests. This panel will address the perspectives behind these numbers and cut through to the facts Are the days of large up-fronts at an end? Pharma’s perspective: huge escalating prices being paid for very early opportunities Is desperation in pharma driving big prices? Does there exist 2-3 year cycles of pharma big up-front investment? Biotech’s perspective: deals becoming both smaller and tranched Payments from both investors and pharma increasingly tied to meeting drug development goals Contingent value rights – are they here for the long term or will they drift into obscurity? Impacts on biotech R&D investments and activities 5-10 year analysis: Looking at the facts Does paying big up front lead to wins? Where are the superstars now? Therapeutic area break-down Assessing a payment realistically, how to conduct win-win negotiation when there are companies paying huge amounts Denise Goode Executive Transaction Director, AstraZeneca Denise Goode, BSc ACA, joined AstraZeneca in 1994 and has been dealmaking for over 10 years.After graduating in biological sciences and qualifying as a Chartered Accountant in the UK, Denise’s Pharmaceutical career started in finance with PwC and then with AstraZeneca. Denise has worked all over the World on all aspects of strategic rev [read more] Ian Nicholson Chief Executive Officer, Chroma Therapeutics Ltd Ian Nicholson joined Chroma in September 2004. Prior to joining Chroma, he was Senior Vice President of Business Development for Celltech, responsible for all global licensing activities, and additionally held the position of Acting CEO, Oxford GlycoSciences following its acquisition by Celltech. Prior to this he was Commercial Director [read more] David Colpman Senior Vice President, Business Development, Shire Pharmaceuticals David Colpman is a senior member of Shire’s business development team focused on building the global speciality business through licensing and M&A.During the last eleven years at Shire, David has completed around 10 licensing deals. In addition he has run numerous M&A, product divestment and acquisition projects. Specific achievem [read more]

Stream A: Payers Perspectives: A key part of the innovat...Stream B: Behind Closed Doors - Deal trends and case stu... 11.30 Breakout Session: Reverse engineering drug development to meet changing payer requirements – Biotech portfolio management in a new era of reimbursement Stream A: Payers Perspectives: A key part of the innovation process Jan Posthumus, Head of Global Market Access and Market Research, Basilea Pharmaceutica It’s clear that in order to launch a successful product, reimbursement needs to be taken into account far earlier in the development lifecycle than in the past, yet many biotechs are not addressing this need. As a result they may spend many years and burn millions developing a product, only to find that there is no sustainable market for it along with missing out on key opportunities from increasingly payer-conscious pharma partners. This session addresses some of the strategic decisions taken into consideration by successful biotech entrepreneurs, outlines how they’ve built a pipeline of differentiated candidates and provides you with a clear guideline to ensuring a reimbursement-ready pipeline. Sufficiently differentiated – what does this really mean? Attractiveness to payers Understood enough to pass regulatory bodies Evaluating product viability Developing a diversified candidate portfolio Balancing clinically validated vs. first in class Clinical and economic evidence development Jan Posthumus Head of Global Market Access and Market Research, Basilea Pharmaceutica Jan Posthumus, MBA, is Global Head Market Access and Market Research at Basilea Pharmaceuticals in Basel, Switzerland.In more than 15 years of professional experience in the pharmaceutical industry, he served in several senior management positions as Director Market Access (Novartis Global, Basel), member of the management team of Novar [read more] 11.30 Powerpoint-free, off the record case study Stream B: Behind Closed Doors - Deal trends and case studies Simon Dew, Vice President Business Development & Early Phase Commercial Development, Astellas Michael Boretti, Associate Director, Business Development, AVEO Pharmaceuticals Astellas / Aveo: The anatomy of a mixed marriage – Or how a young US biotech company and a major Japanese pharma company arrived at the altar Hear an honest, off-the-record, recounting of the details behind the negotiation of the 2011 Scrip Licensing Deal of the Year: What were the primary goals of each company as they headed to the negotiating table? How successful were they in attaining those goals? What were the negotiating challenges? How do you make a 50/50 profit-share work in practice? Simon Dew Vice President Business Development & Early Phase Commercial Development, Astellas Michael Boretti Associate Director, Business Development, AVEO Pharmaceuticals Michael Boretti joined AVEO Pharmaceuticals in 2008, where he currently is responsible for business development. In his time at AVEO, he has helped establish transformative partnerships with Astellas, Biogen Idec, and OSI Pharmaceuticals. Prior to joining AVEO, he worked in the Life Sciences Practice at L.E.K. Consulting where he led strategic projects for both [read more]

Networking LuncheonSpeaker’s CornerLive demonstration: 12.10 Networking Luncheon Networking Luncheon Networking Luncheon 12.10 Speaker’s Corner Speaker’s Corner During the break, visit an area of the event dedicated to interaction with the previous session’s speakers and panellists. This is your opportunity to network and speak openly about any questions not covered during their session. 12.10 Due diligence: the partner's perspective - Dramatically speeding up the due diligence process and give the right impression to your potential partners Live demonstration: William Brown, Regional Director - Life Sciences, DataSite, Merrill DataSite Navigating the data room Using advanced search tools to get to information quickly Tracking and responding quickly and securely to partner inquiries William Brown Regional Director - Life Sciences, DataSite, Merrill DataSite Will Brown has been with Merrill DataSite since July 2007 and brings with him over 10 years of IT Technical and Management experience.Will, formally responsible for DataSite clients in the UK and in Italy, and more recently Quebec Canada, is now based in Paris from where he heads up DataSite's European Life Sciences division. During tim [read more]

12.00 Case Study: Demonstrating value for patients, payers and providers through innovative collaborations between BioPharma and Payers Payers Perspectives: A key part of the innovation process Tehseen Salimi, VP, Global Evidence & Value Development Medical Affairs, Sanofi Jon Williams, SVP, Strategy and Business Development, Medco - United BioSource Corporation The recent deals between Sanofi-Medco along with AstraZeneca-Healthcore have Pharma companies teaming up with insurers to determine what development programs are going to create the most patient benefit and obtain the cost effectiveness data that will be required.With several post-approval failures due to reimbursement, these deals signal a shift away from the mid-Phase III reviews typical of the past towards intervention in early phase trial design and portfolio management.This case study looks at what drove Sanofi and Medco to tie the knot and how payers will be crucial to guiding pharma along the path from laboratory to formulary placement, not just for Sanofi but for the entire BioPharma industry. Origins of the deal and what makes it unique Key drivers, objectives and 5 year outcomes sought Keeping confidentiality: overcoming legal and ethical aspects and ensuring separation Tehseen Salimi VP, Global Evidence & Value Development Medical Affairs, Sanofi Dr. Tehseen Salimi, MD, MHA is the Vice President of the Global Evidence and Value Development, Medical Affairs, Research and Development at Sanofi. She is an innovative and impactful medical executive with 20+ years of deep clinical and corporate experience in the healthcare industry. She has strong involvement in managed care and global pharmaceutical arenas. [read more] Jon Williams SVP, Strategy and Business Development, Medco - United BioSource Corporation Jon Williams leads Medco-UBC’s Strategy and Business Development efforts and is responsible for creating custom solutions for the biopharma industry that leverage Medco and its affiliates’ unique set of capabilities.He has more than twelve years consulting experience in the healthcare industry, where he has worked extensively with big p [read more]

14.00 Panel: Cutting out the middleman – The growing importance of academia to the future of Pharma’s R&D pipelines Payers Perspectives: A key part of the innovation process Jane Buus Laursen, Business Development Director, AstraZeneca Nigel Pitchford, MD Healthcare Investment, Imperial Innovations Kim Bill, Business Development, Nestlè Health Science David Reynolds, Executive Director, External R&D Innovation, Pfizer Professor Alan Dickson, Director, Centre of Excellence in Biopharmaceuticals, The University of Manchester Driven in part by the dearth of VC available for early stage start-ups and competition for late stage in-licensing candidates, the strategic view of academia has changed dramatically in recent years as Pharma look earlier in the development pipeline for promising opportunities and collaborations.This discussion will cover recent examples of academic/industry collaborations including the variations in size and scope, the unique challenges they face in balancing different cultures and an assessment of how well this partnering model is working. The challenge of engaging directly with academia The gap between the reality of drug discovery/development and academia Programmes to educate and build a translational mindset Retaining the knowledge in the development team How is pharma engaging academia currently? Accessing promising technologies and filling capability gaps Analysing successful and failed collaborations – what went wrong and what does this mean for the future of pharma-academic relationships? The alignment of incentives How the model is evolving Are pharma-academic deals a threat to early stage VC? What deals will and won’t work in the long term Strengthening the industry as a whole vs. stifling true innovation Chair: Kim Bill Jane Buus Laursen Business Development Director, AstraZeneca Jane Buus Laursen, Business Development Director at AstraZeneca, joined the Company in 2003 as a senior scientist and project leader for discovery projects in the cardiovascular and metabolism area.In 2009 she moved on to business development in AstraZeneca’s Strategic Partnering & Business Development organisation where [read more] Nigel Pitchford MD Healthcare Investment, Imperial Innovations Nigel is an experienced healthcare venture investor with a strong track record of creating and realising value. He joined Innovations in January 2012 from DFJ Esprit, where as a partner he has been responsible for leading their healthcare activities across Europe. Prior to that, Nigel worked at 3i for 12 years, becoming a Partner in 2006 and ultimately leading their venture health [read more] Kim Bill Business Development, Nestlè Health Science Kim heads up the metabolic health / diabetes platform and is principally looking to build up holistic and integrated personalized healthcare solutions for the management of the metabolic (diabetic) condition through the combination of diagnostics, smart devices, medicalised behaviour and medical nutrition, complementing dru [read more] David Reynolds Executive Director, External R&D Innovation, Pfizer David Reynolds is head of Pain & Sensory Disorders licensing within the External R&D Innovation group at Pfizer. He is based at Pfizer’s research unit, Neusentis, in Cambridge, UK. In addition he also scouts in the UK for opportunities across a wide therapeutic area space and looks to establish collaborations between local univers [read more] Professor Alan Dickson Director, Centre of Excellence in Biopharmaceuticals, The University of Manchester

14.40 Off the record Oxford-style debate: Motion: It is impossible to build/maintain a fully integrated, sustainable biotech company Steven Holtzman, EVP Corporate Development, Biogen Idec Edwin Moses, Chief Executive Officer, Ablynx Catherine Sazdanoff, Vice President, Business Development, Takeda Pharmaceuticals John Rountree, Partner, NovaSecta Melanie Senior, Bureau Chief, Europe, Elsevier Business Intelligence, The Pink Sheet Olivier Litzka, Partner, Edmond de Rothschild Investment Partners Motion:The house believes that it is impossible to build/maintain a fully integrated, sustainable biotech companyThe place of the fully integrated, sustai.nable and independent biotech company is subject to very different, diverging opinions. Some say that there will be a few big pharmas, and a bunch of little companies doing discovery and handing off to them, making it virtually impossible to achieve this goal. On the other side of the argument, others believe there is a place for innovative, end-to-end and commercially viable biotechs in the future biopharma landscape. Hear the perspectives of several key opinion leaders present their market perspectives and make a case for the future of the fully integrated biotechnology company. Once you’ve heard their arguments, vote with your feet and decide where you think the future of Biotech lies. Can a start-up create a full integrated pharma company / create enormous value for shareholders Is there a place for existing mid-sized companies to stay/prosper Can they maintain themselves, become bigger and self sustaining Could they avoid becoming the target of acquisition Is there the case that they would see it being positive for them to merge with a larger company? What it would take to attain this goal Staying focused in areas with forward integration ability Staying small enough to foster innovation but big enough to attain scale Moderator: Melanie Senior, Bureau Chief, Europe, Elsevier Business Intelligence, The Pink Sheet Olivier Litzka, Partner, Edmond de Rothschild Investment Partners >> Against Motion  Steven Holtzman, Executive Vice President, Corporate Development, Biogen Idec >> Against Motion  John Rountree, Partner, NovaSecta >> Against Motion Catherine Sazdanoff, Vice President, Business Development, Takeda Pharmaceuticals >> For Motion  Edwin Moses, CEO, Ablynx >> For Motion  Steven Holtzman EVP Corporate Development, Biogen Idec Steven H. Holtzman joined Biogen Idec (NASDAQ: BIIB) in early 2011 as its Executive Vice President, Corporate Development in which capacity he is responsible for Corporate Strategy and M&A, Business Development, and Program Leadership & Management. From 2001-2010, Steve served as a Founder, the CEO and Chair of the Board of Direct [read more] Edwin Moses Chief Executive Officer, Ablynx After completing his post-doctoral research in Germany, Edwin Moses began a commercial career with successful periods spent at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001, first as CEO and later as Chairman, he was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a flotation (LSE) in [read more] Catherine Sazdanoff Vice President, Business Development, Takeda Pharmaceuticals Catherine Sazdanoff joined Takeda’s Global Business Development & Licensing group in December 2006, and became Vice President, Global Licensing in May 2008 after the Millennium acquisition. She subsequently became VP, Corporate Development focusing on global M&A projects, and most recently was co-lead on the Nycomed acquisition in [read more] John Rountree Partner, NovaSecta John Rountree is the Managing Partner of NovaSecta, the specialist 'MidPharma' consulting firm. He has over 25 years of experience in management consulting and creating value with all sizes of pharmaceutical and biotech firms worldwide. He founded NovaSecta in 2003 and has built the company with a focus on mid-sized pharmaceutical and biotech companies, working [read more] Melanie Senior Bureau Chief, Europe, Elsevier Business Intelligence, The Pink Sheet As Bureau Chief, Europe, for Elsevier Business Intelligence, Melanie Senior is responsible for European biopharma content within the company’s flagship health care publications, In Vivo, The In Vivo Blog, Start Up and the Pink Sheet. She has covered the industry for over 10 years, with particular interest in biotech and pharmaceutical dealmaking and strategy, sp [read more] Olivier Litzka Partner, Edmond de Rothschild Investment Partners Olivier joined the Life Sciences team in 2006. He worked with 3i in Venture Healthcare, with the first four years in Munich and the last two in Paris. Prior to that Olivier was a consultant with Mercer Management Consulting in Munich and Paris. Olivier holds a PhD in Biology from the Munich Institut für Genetik und Mikrobiologie and has [read more]

Afternoon Coffee & Chairman’s closing re...Speaker’s Corner 15.40 Afternoon Coffee & Chairman’s closing remarks & close of conference Afternoon Coffee & Chairman’s closing remarks & close of conference Afternoon Coffee & Chairman’s closing remarks & close of conference 15.40 Speaker’s Corner Speaker’s Corner During the break, visit an area of the event dedicated to interaction with the previous session’s speakers and panellists. This is your opportunity to network and speak openly about any questions not covered during their session.